Wall Street analysts expect Scholar Rock Holding Co. (NASDAQ:SRRK – Get Rating) to announce ($0.68) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Scholar Rock’s earnings, with the lowest EPS estimate coming in at ($1.16) and the highest estimate coming in at ($0.16). Scholar Rock posted earnings per share of ($0.76) during the same quarter last year, which indicates a positive year over year growth rate of 10.5%. The firm is expected to issue its next earnings results on Monday, January 1st.
On average, analysts expect that Scholar Rock will report full year earnings of ($3.96) per share for the current year, with EPS estimates ranging from ($4.37) to ($3.18). For the next financial year, analysts anticipate that the company will post earnings of ($4.30) per share, with EPS estimates ranging from ($5.99) to ($3.20). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that cover Scholar Rock.
Scholar Rock (NASDAQ:SRRK – Get Rating) last issued its quarterly earnings data on Monday, March 7th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($1.05) by $0.08. The business had revenue of $4.05 million for the quarter, compared to the consensus estimate of $4.33 million. Scholar Rock had a negative net margin of 700.46% and a negative return on equity of 64.57%. During the same period in the previous year, the firm earned ($2.81) EPS.
Scholar Rock stock traded up $0.22 during mid-day trading on Monday, reaching $10.12. 30,655 shares of the company traded hands, compared to its average volume of 288,856. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.13 and a quick ratio of 4.13. The stock’s 50 day moving average price is $14.67. The stock has a market capitalization of $357.21 million, a price-to-earnings ratio of -2.79 and a beta of 0.24. Scholar Rock has a 52-week low of $9.50 and a 52-week high of $44.95.
A number of institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Scholar Rock by 4.1% in the 4th quarter. BlackRock Inc. now owns 2,288,026 shares of the company’s stock worth $56,835,000 after purchasing an additional 89,921 shares in the last quarter. Wellington Management Group LLP boosted its stake in Scholar Rock by 124.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company’s stock worth $42,150,000 after purchasing an additional 708,831 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Scholar Rock by 25.9% in the 4th quarter. Victory Capital Management Inc. now owns 1,273,193 shares of the company’s stock worth $31,626,000 after purchasing an additional 262,130 shares in the last quarter. State Street Corp boosted its stake in Scholar Rock by 4.1% in the 4th quarter. State Street Corp now owns 1,246,877 shares of the company’s stock worth $30,972,000 after purchasing an additional 49,411 shares in the last quarter. Finally, Norges Bank bought a new position in Scholar Rock in the 4th quarter worth about $14,267,000. Institutional investors own 82.42% of the company’s stock.
About Scholar Rock (Get Rating)
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.
- Get a free copy of the StockNews.com research report on Scholar Rock (SRRK)
- Banking On Bank Of America
- Major Shareholder Bets Big On Nielson Holdings plc
- Tapestry Stock is a Value Play Down Here
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scholar Rock Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scholar Rock and related companies with MarketBeat.com's FREE daily email newsletter.